Thyrocare Technologies Share Price

Healthcare Services company Thyrocare Technologies announced Q4FY26 & FY26 results Financial Highlights: Consolidated revenue from operations for Q4FY26 stood at Rs 223.95 crore, representing a YoY growth of 20% compared to Rs 187.16 crore in Q4FY25. For FY26, the company reported consolidated revenue from operations of Rs 829.04 crore, an increase of 21% YoY from Rs 687.35 crore in FY25. The consolidated reported EBITDA for Q4FY26 was Rs 75.09 crore, marking a 31% YoY increase from Rs 57.39 crore in Q4FY25. Normalized EBITDA for Q4FY26 reached Rs 78.52 crore, reflecting a 20% YoY growth compared to Rs 65.29 crore in the same quarter last year. For FY26, the consolidated EBITDA stood at Rs 262.04 crore, up 38% YoY, while Normalized EBITDA reached Rs 279.86 crore, registering a growth of 33% YoY. Profit After Tax (PAT) for Q4FY26 surged by 128% YoY to reach Rs 48.70 crore, as against Rs 21.34 crore in Q4FY25. Annual Profit After Tax (PAT) for FY26 was Rs 162.85 crore, a growth of 81% YoY compared to Rs 89.98 crore in FY25. Profit Before Tax (PBT) for Q4FY26 stood at Rs 64.43 crore, reflecting an 81% YoY increase from Rs 35.72 crore. For the financial year FY26, PBT was reported at Rs 212.88 crore, an increase of 60% YoY from Rs 132.25 crore in FY25. Other income for Q4FY26 was Rs 4.31 crore, while For FY26, it stood at Rs 16.99 crore. Business Highlights Segment Performance: In the Pathology business, franchise revenue grew by 21% YoY in Q4FY26 and 18% YoY for FY26. Partnership revenue within the Pathology business recorded a YoY growth of 23% in Q4FY26 and a robust 32% YoY growth for FY26. Normalised partnership revenue for Q4FY26 grew by 32% after adjusting for one-off camp revenue from the previous year. Operational Volume: Thyrocare processed 59.0 million tests in Q4FY26, marking a 29% YoY growth. For FY26, test volumes reached 209.6 million, a growth of 23% YoY. Expansion Initiatives: The company expanded its test portfolio by adding over 250 SKUs in advanced allergy testing on the Phadia platform. Thyrocare forayed into genomics with a state-of-the-art laboratory and the launch of Non-invasive Pre-Natal Testing (NIPT). Quality and Turnaround: The company maintained Six Sigma quality standards, reducing complaints per million tests to 3.1, a 34% YoY reduction. The company achieved an Average Turnaround Time (ATAT) of 3.43 hours from sample receipt, becoming the first diagnostic chain in India to hit this benchmark. Network Reach: Thyrocare currently maintains a quarterly active franchise count of approximately 10,800 across India. Rahul Guha, MD & CEO, Thyrocare Technologies, said: “Thyrocare reported a strong performance this quarter, driven by continued focus on operational efficiency, network expansion, and value-driven diagnostics. During the period, we also strengthened our specialty portfolio with the addition of allergy testing and entry into genomics through the launch of NIPT, with a phased expansion of the test menu underway. Thyrocare continues to expand its reach in underserved regions and scale its franchise and partner network, while remaining committed to delivering high-quality, affordable healthcare services across India.” Result PDF

• Trendlyne
• 1 month 1 week ago

Thyrocare reported a strong performance for the Q3FY26, with consolidated profit after tax (PAT) after exceptional items rising 80 per cent to 34.07 crore from 18.94 crore in the year-ago period

• Business Standard
• 4 months 3 weeks ago

Healthcare Services company Thyrocare Technologies announced Q3FY26 results Consolidated revenue registered a 18% YoY growth, driven primarily by a 20% increase in the Pathology segment. In the Pathology business, franchise revenue grew by 12% YoY, while partnership revenue including pharmeasy business recorded a robust 39% YoY growth. Thyrocare, India’s largest diagnostic test volume processor, processed 49.6 million tests in Q3FY26, marking a strong 22% YoY growth and reinforcing its leadership position in the diagnostics industry. Consolidated EBITDA grew by 38% YoY, and Profit After Tax (PAT) grew by 47% YoY to Rs 27.91 crore after considering exceptional items relating to non-recurring labour code & bonus issue impact. Achieved Six Sigma quality standards (defined as 3.4 CPMT), reducing complaints per million tests to 3.2 (down 43% YoY) with ATAT at 3.28 hours - India's first diagnostic chain to hit this benchmark. Rahul Guha, MD & CEO, Thyrocare Technologies, said: “We are pleased to report a robust set of results for the quarter. These numbers underscore our continued focus on operational excellence, network expansion, and value-driven diagnostics. As we deepen our presence in underserved regions and scale our franchise and partner channels, we remain committed to delivering high-quality, affordable healthcare services across India.” Result PDF

• Trendlyne
• 4 months 3 weeks ago